The Kidney-Heart Connection: Why eGFR Matters

The kidneys and the heart share risk factors and influence each other through blood pressure, fluid balance, and vascular health. Declining eGFR and rising albuminuria raise cardiovascular risk in a graded pattern — which is why the AHA PREVENT equations count kidney function among their inputs.

The kidneys filter about 180 liters of blood-derived fluid each day — and their filtration rate carries direct information about cardiovascular risk.

Chronic kidney disease and cardiovascular disease share the same major risk factors — hypertension and diabetes — and each condition amplifies the other. As estimated glomerular filtration rate (eGFR) declines and urine albumin levels rise, cardiovascular risk rises in a graded pattern, which is why the 2023 AHA PREVENT equations include eGFR (and optionally UACR) as inputs alongside traditional risk factors.¹³

This connection surprises many people. The kidneys sit far from the heart, and kidney problems often develop without symptoms. Yet large studies have shown that people with reduced kidney function experience heart attacks, heart failure, and cardiovascular death at rates far above the general population — even after accounting for blood pressure, cholesterol, and diabetes.⁴⁹ The relationship runs in both directions: a failing heart can injure the kidneys, and failing kidneys strain the heart.

Understanding this connection helps explain why modern risk calculators ask about kidney function. The sections below cover how the two organs are linked, what eGFR actually measures, how chronic kidney disease stages map to heart risk, what albuminuria reveals, and how the PREVENT equations changed cardiovascular risk prediction.

How the Kidneys and Heart Are Linked

The heart and kidneys form a circulatory partnership. The heart pumps blood; the kidneys receive roughly 20 to 25 percent of cardiac output despite weighing less than 1 percent of body weight. That high blood flow exists for a reason: each day, the kidneys filter around 180 liters of blood-derived fluid through tiny capillary tufts called glomeruli, reclaiming water, salts, and nutrients while excreting waste.

Because the kidneys are so vascular, they share the same vulnerabilities as the heart's own arteries. Hypertension damages the small vessels of the kidney just as it damages coronary and cerebral arteries. Diabetes injures the glomerular filter through years of elevated blood sugar. These two conditions — hypertension and diabetes — are the leading causes of chronic kidney disease worldwide and among the strongest risk factors for cardiovascular disease.¹

Physiologically, the organs talk to each other through several pathways. The kidneys control blood volume and blood pressure by adjusting sodium and water excretion. They regulate electrolytes such as potassium, whose balance the heart's electrical system depends on. They produce hormones, including erythropoietin (which stimulates red blood cell production) and renin, the starting point of the renin-angiotensin-aldosterone system that constricts blood vessels and raises blood pressure.

When kidney function declines, these regulatory jobs falter. Fluid retention raises blood pressure and cardiac workload. Potassium and acid-base disturbances can disturb heart rhythm. Anemia from reduced erythropoietin production forces the heart to pump harder to deliver oxygen. Uremic toxins — waste products the kidneys can no longer clear — promote vascular calcification and inflammation. Each mechanism adds cardiovascular load.¹¹

The American Heart Association formalized this overlap in its 2023 advisory on cardiovascular-kidney-metabolic (CKM) syndrome, describing heart disease, kidney disease, and metabolic disorders as interconnected rather than separate conditions.⁸ Cardiologists and nephrologists also use the concept of cardiorenal syndrome: an organized framework, first codified by Ronco and colleagues, describing how acute or chronic dysfunction in one organ triggers dysfunction in the other.⁷ For example, an acute heart failure episode can drop kidney perfusion and cause acute kidney injury (type 1 cardiorenal syndrome), while progressive chronic kidney disease can drive heart failure through volume overload and hypertension (type 4).

The result of all these pathways is measurable. In a landmark study of more than one million adults, Go and colleagues found that the risk of cardiovascular events, hospitalization, and death rose steadily as kidney function fell — a graded relationship that persisted after adjustment for blood pressure, diabetes, cholesterol, and other factors.⁹ A meta-analysis by the CKD Prognosis Consortium, pooling over two million participants, confirmed that lower eGFR and higher albuminuria each independently predicted cardiovascular mortality.⁴ The heart and kidneys do not fail in isolation; their fates are tied.

eGFR Explained

eGFR stands for estimated glomerular filtration rate. It estimates the volume of fluid the kidneys filter through the glomeruli each minute, standardized to a body surface area of 1.73 square meters. The units — mL/min/1.73m² — express how many milliliters of plasma the kidneys clear per minute, scaled to a typical adult body size so that values are comparable between people.

True glomerular filtration rate can only be measured directly with specialized tracer techniques, which are impractical for routine care. Instead, laboratories estimate it from serum creatinine, a waste product of muscle metabolism that the kidneys filter at a relatively steady rate. When filtration slows, creatinine accumulates in the blood, so higher serum creatinine implies lower eGFR. Equations convert the creatinine value into an eGFR using the patient's age and sex, since muscle mass — and therefore creatinine production — varies with both.⁶

The standard estimating equation today is the 2021 CKD-EPI creatinine equation, developed by Inker and colleagues and published in the New England Journal of Medicine.⁵ It replaced the 2009 CKD-EPI equation by removing the race coefficient, which had adjusted estimates for Black patients based on population-average creatinine differences. Researchers concluded that race is a social, not biological, construct and that the adjustment reduced accuracy for some individuals. The 2021 equation estimates GFR from creatinine, age, and sex alone. A combined creatinine-plus-cystatin C version exists and is more accurate, but cystatin C testing is less widely available.

An eGFR of 90 or above is considered normal filtration (in the absence of other kidney damage markers). Values between 60 and 89 indicate mildly decreased function. Below 60, sustained over three months with or without albuminuria, meets the diagnostic threshold for chronic kidney disease under KDIGO 2024 criteria.¹ A single low reading does not establish CKD — dehydration, certain medications, and high-protein meals can temporarily shift creatinine — which is why guidelines require persistence over at least three months.

eGFR is not a perfect measure. Because it rests on creatinine, anything that changes muscle mass or creatinine production can distort it: very muscular or very frail individuals, amputees, and people with rapidly changing kidney function (such as during acute illness) may get misleading estimates. Clinicians interpret eGFR alongside trends over time, urine findings, and the clinical picture. For quick reference, the GFR calculator on this site applies the 2021 CKD-EPI equation to serum creatinine, age, and sex inputs, and the creatinine clearance calculator offers the older Cockcroft–Gault estimate used for drug dosing.

CKD Stages and Heart Risk

The KDIGO 2024 guideline classifies chronic kidney disease using two dimensions: eGFR category (G1 through G5) and albuminuria category (A1 through A3) — a framework first established by the 2012 KDIGO CKD guideline.¹² The eGFR categories describe how much filtration has been lost; combining them with albuminuria produces a "heat map" of overall risk. For cardiovascular risk specifically, both dimensions matter — and risk rises along both axes.

The graded pattern is the key insight. Cardiovascular risk does not appear suddenly at kidney failure — it climbs stage by stage. In the CKD Prognosis Consortium meta-analysis, each 15 mL/min/1.73m² drop in eGFR below 60 was associated with higher cardiovascular mortality, and the curve steepened at lower eGFR levels.⁴ The Go et al. study found a similar stepwise increase in the adjusted risk of death, cardiovascular events, and hospitalization across eGFR categories in over a million adults.⁹

After a heart attack, kidney function also predicts recovery. Anavekar and colleagues showed that among patients who survived a myocardial infarction, lower eGFR was associated with higher rates of subsequent cardiovascular events and death — a finding that held across the full range of kidney function, not just at the severe end.¹⁰ This illustrates the two-way traffic: kidney dysfunction worsens cardiac outcomes, and cardiac injury stresses the kidneys.

Guidelines reflect this evidence. The KDIGO 2024 CKD guideline recommends that people with chronic kidney disease receive cardiovascular risk assessment as part of routine care, since cardiovascular events — not progression to kidney failure — are the most common adverse outcome for most CKD patients.¹ This is precisely why eGFR earned a place in modern cardiovascular risk equations.

Albuminuria and UACR

While eGFR measures how much the kidneys filter, albuminuria measures how well the filter holds back what it should. Albumin is a protein that circulates in the blood; healthy glomeruli keep almost all of it out of the urine. When the glomerular barrier is damaged — by hypertension, diabetes, or inflammation — albumin leaks into the urine.

The standard measure is the urine albumin-to-creatinine ratio, or UACR, expressed in milligrams of albumin per gram of creatinine (mg/g). Dividing by urine creatinine corrects for how concentrated or dilute the urine sample is, so a random spot urine sample works — no 24-hour collection needed. KDIGO 2024 prefers a first-morning sample when possible, since it is less affected by daytime activity and posture.¹

Why does a urine finding predict heart events? Researchers view albuminuria as a window into the body's blood vessels. The same endothelial injury that lets albumin slip through the glomerular filter also affects arteries throughout the body — the coronary arteries included. Albuminuria correlates with systemic inflammation, arterial stiffness, and endothelial dysfunction, all of which drive atherosclerosis. Gansevoort and colleagues described albuminuria as a marker of generalized vascular damage rather than a purely kidney-local finding.¹¹

Crucially, albuminuria predicts cardiovascular risk independently of eGFR. In the CKD Prognosis Consortium's pooled cohorts, people with elevated UACR but preserved eGFR still faced higher cardiovascular mortality than those with normal urine findings.⁴ This independence is exactly why risk models benefit from including both measures: eGFR captures filtration loss, while UACR captures vascular injury — and the two do not always move together.

Why PREVENT Includes Kidney Measures

For a decade, the dominant cardiovascular risk tool was the Pooled Cohort Equations (PCE), published in the 2013 ACC/AHA guideline. The PCE estimated 10-year risk of atherosclerotic events from age, sex, race, blood pressure, cholesterol, smoking, and diabetes status. It worked well for its purpose — but it had no kidney input at all. A person with an eGFR of 35 and a person with an eGFR of 95 received the same score if their other inputs matched, despite very different cardiovascular risk.³

The 2023 AHA PREVENT equations, developed by Khan and colleagues and published in Circulation in 2024, changed that.³ Derived from more than 6 million adults across 25 datasets, PREVENT added eGFR — calculated from serum creatinine — as a core predictor in its base model. It also accepts optional inputs that sharpen the estimate: UACR for albuminuria, HbA1c for glycemic control, and a social deprivation index based on ZIP code. The equations predict both 10-year and 30-year risk, and they estimate total cardiovascular disease including heart failure, not just atherosclerotic events.

The decision to include eGFR was data-driven. Validation studies showed that kidney function added predictive power beyond the traditional risk factors — meaning it improved the model's ability to distinguish who would and would not experience events. Omitting it left measurable risk on the table, particularly for the large population with undiagnosed or early-stage CKD. The optional UACR input captures the albuminuria signal described above, which carries independent information even when eGFR is normal.³⁴

This shift mirrors a broader clinical trend. The AHA's cardiovascular-kidney-metabolic syndrome advisory argued that heart, kidney, and metabolic health should be assessed together rather than in specialty silos.⁸ Including kidney measures in the flagship risk equations turns that principle into practice: a routine lipid and blood pressure check, plus a basic metabolic panel that yields eGFR, now feeds a single integrated risk estimate.

Readers can compare the models directly. The ASCVD risk calculator on this site implements the classic Pooled Cohort Equations, while the PREVENT calculator uses the newer equations with kidney inputs. Running both with the same profile illustrates how eGFR and UACR shift the estimated risk — a concrete demonstration of the kidney-heart connection in numbers.

BUN/Creatinine Ratio and Other Kidney Markers

Beyond eGFR and albuminuria, clinicians use several other laboratory markers to characterize kidney function. Two of the most common are blood urea nitrogen (BUN) and serum creatinine. Both are waste products cleared by the kidneys, and both rise when filtration falls. The ratio between them, however, carries information that neither value alone provides.

Urea and creatinine are handled differently by the kidney's tubules. Creatinine is filtered and secreted with little reabsorption. Urea is filtered and then partially reabsorbed — and reabsorption increases when blood flow to the kidneys drops, because slower tubular flow gives urea more time to be reclaimed. As a result, when kidney dysfunction stems from low perfusion (a prerenal cause such as dehydration, bleeding, or reduced cardiac output in heart failure), BUN rises disproportionately and the BUN-to-creatinine ratio climbs, often above 20:1 when both are measured in mg/dL. When dysfunction stems from damage within the kidney tissue itself (an intrinsic cause such as acute tubular injury), the two rise more proportionally and the ratio typically stays in the 10:1 to 20:1 range.¹²

This distinction matters for the heart-kidney story. In a patient with heart failure, a rising BUN/creatinine ratio can signal that falling cardiac output is starving the kidneys of blood flow — a type 1 cardiorenal pattern — rather than primary kidney disease. Clinicians interpret the ratio alongside volume status, medication use (diuretics raise urea reabsorption), and the trend over time, not as a standalone verdict.¹²

For finer distinctions, nephrologists use fractional excretion measures: FENa (fractional excretion of sodium) and FEUrea (fractional excretion of urea). In oliguric acute kidney injury, a FENa below 1 percent generally suggests a prerenal cause, while higher values point toward intrinsic tubular damage; FEUrea serves a similar role when diuretics make FENa unreliable. These are specialized calculations used in hospital settings, but they rest on the same principle as the BUN/creatinine ratio — comparing how the tubules handle different solutes to locate the problem.

To explore these markers, the BUN/creatinine ratio calculator on this site computes the ratio from standard lab values and explains the prerenal versus intrinsic interpretation. As with eGFR, a single ratio is a data point; clinicians read it in the context of the full clinical picture.

Protecting Both Organs

Because the heart and kidneys share risk factors, the strategies that protect one tend to protect the other. Both the KDIGO 2024 CKD guideline and AHA cardiovascular guidance emphasize control of the same core risk factors: blood pressure, blood sugar, lipids, and tobacco use.¹⁸ This section summarizes what the guidelines note, framed objectively rather than as personal advice.

Blood pressure. Hypertension is the single most important shared risk factor. Guidelines note that lower blood pressure targets reduce both cardiovascular events and CKD progression, with the KDIGO 2024 guideline supporting a systolic target below 120 mm Hg for many adults with CKD when treatment is tolerated.¹ Blood pressure control protects the glomerular filter from mechanical injury while simultaneously reducing cardiac workload and stroke risk.

Diabetes management. Diabetes drives both diabetic kidney disease and cardiovascular disease through years of elevated blood sugar injuring small and large vessels alike. Studies found that tighter glycemic control early in the course of diabetes slows the development of albuminuria, and the PREVENT equations' optional HbA1c input reflects glycemic control's independent contribution to cardiovascular risk.³ Patients often discuss individualized targets with their clinician, since the right goal varies with age, comorbidities, and hypoglycemia risk.

Lipids. CKD alters lipid metabolism and raises cardiovascular risk even when standard cholesterol panels look unremarkable. KDIGO 2024 recommends statin-based lipid management for adults with CKD who are not on dialysis, based on trial evidence of cardiovascular benefit in this population.¹ The recommendation acknowledges that CKD itself functions as a cardiovascular risk enhancer.

Smoking and lifestyle. Smoking accelerates both CKD progression and atherosclerosis. Guidelines consistently note smoking cessation as beneficial for kidney and cardiovascular outcomes alike. Regular physical activity, maintenance of healthy weight, and diets lower in sodium are associated with better blood pressure control and slower kidney function decline in observational studies.¹¹

Medication awareness. Certain commonly used drugs — including nonsteroidal anti-inflammatory drugs (NSAIDs) — can reduce kidney blood flow and raise blood pressure, affecting both organs. Guidelines advise caution with nephrotoxic medications in CKD, and patients often review their full medication list with their clinician or pharmacist.

The unifying message from the evidence is integration. Kidney function is not a separate concern from heart health; it is part of the same risk picture. That is why eGFR appears on the basic metabolic panel, why albuminuria screening is recommended in diabetes and hypertension, and why the newest risk equations count kidney measures among their inputs.^1,3,8